Get started
GLENMARK PHARMACEUTICALS LTD.GLENMARK PHARMACEUTICALS LTD.GLENMARK PHARMACEUTICALS LTD.

GLENMARK PHARMACEUTICALS LTD.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

GLENMARK chart


Full chart

GLENMARK upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪434.77 B‬ INR
Dividend yield (indicated)
0.16%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−31.00 INR
Net income (FY)
‪−15.02 B‬ INR
Revenue (FY)
‪118.13 B‬ INR
Shares float
‪137.26 M‬
Beta (1Y)
0.55

Employees


Employees (FY)
‪16.29 K‬
Change (1Y)
‪+1.32 K‬ +8.83%
Revenue / Employee (1Y)
‪7.25 M‬ INR
Net income / Employee (1Y)
‪−1.17 M‬ INR

About GLENMARK PHARMACEUTICALS


Sector
Health Technology
CEO
Glenn Mario Saldanha
Headquarters
Mumbai
Website
glenmarkpharma.com
Founded
1977
ISIN
INE935A01035
FIGI
BBG000BJ3V03
Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. It operates through the following geographical segments: India, North America, Europe, Latin America, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GLENMARK news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GLENMARK is 1,499.10 INR — it has decreased by −2.71% in the past 24 hours. Watch GLENMARK PHARMACEUTICALS LTD. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange GLENMARK PHARMACEUTICALS LTD. stocks are traded under the ticker GLENMARK.
GLENMARK stock has fallen by −8.38% compared to the previous week, the month change is a −2.94% fall, over the last year GLENMARK PHARMACEUTICALS LTD. has showed a 72.69% increase.
We've gathered analysts' opinions on GLENMARK PHARMACEUTICALS LTD. future price: according to them, GLENMARK price has a max estimate of 2,036.00 INR and a min estimate of 1,345.00 INR. Watch GLENMARK chart and read a more detailed GLENMARK PHARMACEUTICALS LTD. stock forecast: see what analysts think of GLENMARK PHARMACEUTICALS LTD. and suggest that you do with its stocks.
GLENMARK reached its all-time high on Oct 15, 2024 with the price of 1,830.05 INR, and its all-time low was 19.65 INR and was reached on Nov 5, 2003. View more price dynamics on GLENMARK chart.
See other stocks reaching their highest and lowest prices.
GLENMARK stock is 1.40% volatile and has beta coefficient of 0.55. Track GLENMARK PHARMACEUTICALS LTD. stock price on the chart and check out the list of the most volatile stocks — is GLENMARK PHARMACEUTICALS LTD. there?
Today GLENMARK PHARMACEUTICALS LTD. has the market capitalization of ‪434.77 B‬, it has increased by 0.78% over the last week.
Yes, you can track GLENMARK PHARMACEUTICALS LTD. financials in yearly and quarterly reports right on TradingView.
GLENMARK PHARMACEUTICALS LTD. is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
GLENMARK earnings for the last quarter are 12.55 INR per share, whereas the estimation was 14.70 INR resulting in a −14.63% surprise. The estimated earnings for the next quarter are 13.90 INR per share. See more details about GLENMARK PHARMACEUTICALS LTD. earnings.
GLENMARK PHARMACEUTICALS LTD. revenue for the last quarter amounts to ‪34.34 B‬ INR, despite the estimated figure of ‪34.89 B‬ INR. In the next quarter, revenue is expected to reach ‪34.41 B‬ INR.
GLENMARK net income for the last quarter is ‪3.54 B‬ INR, while the quarter before that showed ‪3.40 B‬ INR of net income which accounts for 4.10% change. Track more GLENMARK PHARMACEUTICALS LTD. financial stats to get the full picture.
Yes, GLENMARK dividends are paid annually. The last dividend per share was 2.50 INR. As of today, Dividend Yield (TTM)% is 0.16%. Tracking GLENMARK PHARMACEUTICALS LTD. dividends might help you take more informed decisions.
As of Jan 14, 2025, the company has ‪16.29 K‬ employees. See our rating of the largest employees — is GLENMARK PHARMACEUTICALS LTD. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GLENMARK PHARMACEUTICALS LTD. EBITDA is ‪14.86 B‬ INR, and current EBITDA margin is 10.43%. See more stats in GLENMARK PHARMACEUTICALS LTD. financial statements.
Like other stocks, GLENMARK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GLENMARK PHARMACEUTICALS LTD. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GLENMARK PHARMACEUTICALS LTD. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GLENMARK PHARMACEUTICALS LTD. stock shows the buy signal. See more of GLENMARK PHARMACEUTICALS LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.